
Selank Nasal Spray
Selank — nasal spray formatThis listing supplies the compound as a pre-mixed nasal spray rat...

Vial products ship as dry lyophilized material unless the product format explicitly states otherwise.
Per-unit price drops automatically as quantity increases.
| Strength | 1 | 2+ | 5+ |
|---|---|---|---|
| 10mg | $110.00 | $104.50 | $99.00 |
Per-unit pricing at each quantity break, applied automatically at checkout.
Your lot number is stamped on the base of the vial or bottle. Match it to the list to open the certificate for the exact material you received.
PT-141 (bremelanotide) is a melanocortin receptor agonist evaluated in phase 3 trials for acquired generalized hypoactive sexual desire disorder in premenopausal women.
In two identical phase 3 RECONNECT trials, bremelanotide increased FSFI desire-domain scores and reduced desire-related distress versus placebo.
An open-label extension of the RECONNECT program reported sustained desire-domain and distress-score changes with continued as-needed bremelanotide use.
In a phase 2b trial in premenopausal women with female sexual dysfunctions, subcutaneous bremelanotide increased satisfying sexual events and FSFI scores versus placebo.
These summaries describe findings reported in published laboratory and clinical literature about this compound. They are provided for research context only. They are not claims about this product, and nothing here describes an intended use in humans or animals. This material is supplied strictly for laboratory research use.
This listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.
Because this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized PT-141 (Bremelanotide) vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.
melanocortin receptor agonist peptide
PT-141, also known as bremelanotide, is a cyclic melanocortin analog studied for effects on central melanocortin pathways rather than vascular PDE5 signaling. Published studies examine subjective arousal, erectile-response measurements, pharmacokinetics, tolerability, and melanocortin receptor biology. Its research profile is distinct from metabolic melanocortins because MC4R-linked CNS signaling is a major focus.
Bremelanotide has an FDA-approved counterpart, Vyleesi, for a specific approved indication and labeled route. Research-grade PT-141 powder is not Vyleesi, is not an approved drug product, is Research Use Only, and is not for human consumption. Reported ranges below describe published clinical research or approved-product contexts as reference information only.
PT-141 activates melanocortin receptors, especially MC4R-relevant pathways in the central nervous system. Unlike PDE5 inhibitors, its studied effects are not primarily mediated by direct peripheral vasodilation. Research models focus on hypothalamic and limbic signaling, dopamine-related arousal circuits, and downstream autonomic effects. Because melanocortin receptors are distributed across tissues, pharmacodynamic work also tracks nausea, flushing, blood pressure, and route-dependent exposure.
Fields of active investigation, not claims. Investigation is not proof.
PT-141 is studied by neuropharmacologists, sexual-medicine researchers, peptide chemists, and clinical pharmacology teams. Regulatory researchers distinguish approved bremelanotide products from research-grade material because formulation, labeling, and quality systems are not interchangeable.
What published research and laboratory protocols document. These describe what was studied — they are not instructions, recommendations, or a protocol for use.
| Reported amount | Frequency | Route | Research context |
|---|---|---|---|
| 300 mcg – 10 mg | single study administration | subcutaneous | Subcutaneous PT-141 clinical pharmacology study |
| 7.5 mg | single crossover study administration | intranasal | Intranasal PT-141 plus sildenafil study in men with erectile dysfunction |
| 1.75 mg | as labeled for the approved product | subcutaneous | FDA-approved bremelanotide product label context |
Research-grade lyophilized PT-141 is commonly stored cold, dry, and protected from light; reconstituted research solutions are generally refrigerated and used within the supplier's stated stability window.
PT-141 has been studied with PDE5-inhibitor contexts, but combining centrally active melanocortin signaling with other pharmacology changes safety and interpretation. Research designs should distinguish approved bremelanotide products from RUO PT-141 and should not convert clinical exposure data into personal protocols.
| Purity | ≥99.0% by HPLC |
|---|---|
| Physical form | See product format |
| Third-party laboratory | AxisPharm, LLC |
| Lots with COA on file | 1 |
| Also referred to as | bremelanotide, PT-141, melanocortin receptor agonist |
| Reported half-life | Bremelanotide is commonly described with an elimination half-life of roughly 2-3 hours in clinical pharmacology contexts. |
Identity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.
what is the dosage for PT-141
Published PT-141 studies include subcutaneous and intranasal exposure ranges, and Vyleesi has its own approved label. Research-grade PT-141 is not Vyleesi and is not for human consumption.
how much bacteriostatic water for PT-141
Reconstitution examples often use 1-2 mL for 5-10 mg research vials. That only sets concentration for lab calculations.
PT-141 dosage per day
PT-141 is not usually framed as a daily research compound in the core clinical literature. Frequency should be taken from the specific study being discussed.
PT-141 dosage chart
A chart should keep subcutaneous study exposures, intranasal studies, and approved Vyleesi labeling in separate rows.
how long does PT-141 take
Clinical studies measure pharmacodynamic effects over hours after administration. Timing depends on route, formulation, and endpoint.
PT-141 half life
Bremelanotide is commonly cited around a 2-3 hour elimination half-life, though observed effects and study windows can extend beyond that.
can PT-141 be stacked
It has been studied in combination contexts, but that is not a personal-use endorsement. RUO PT-141 should not be used as an approved drug substitute.
Every reference below resolves to an indexed paper. We would rather cite less and cite accurately.
For laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications. This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.
Most peptides sold in this category are imported in bulk, repackaged, and sold with no paperwork attached to the material in the bottle. Ours are synthesized in United States laboratories and every lot carries its own certificate.